|
1
|
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
|
J Clin Oncol
|
2005
|
3.62
|
|
2
|
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
|
J Clin Oncol
|
2005
|
2.77
|
|
3
|
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.
|
J Clin Oncol
|
2010
|
2.51
|
|
4
|
The proteasome as a target for cancer therapy.
|
Clin Cancer Res
|
2003
|
2.13
|
|
5
|
A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.
|
Gastrointest Cancer Res
|
2009
|
1.12
|
|
6
|
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
|
Clin Cancer Res
|
2009
|
1.04
|
|
7
|
Antiangiogenic therapies for advanced hepatocellular carcinoma.
|
Oncologist
|
2013
|
0.94
|
|
8
|
Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options.
|
Expert Opin Investig Drugs
|
2009
|
0.91
|
|
9
|
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
|
Oncology
|
2012
|
0.88
|
|
10
|
Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma.
|
J Clin Oncol
|
2009
|
0.84
|
|
11
|
Targeted therapies for hepatocellular carcinoma.
|
Clin Adv Hematol Oncol
|
2008
|
0.81
|
|
12
|
GI-4000 in KRAS mutant cancers.
|
Expert Opin Investig Drugs
|
2013
|
0.78
|
|
13
|
Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
|
Invest New Drugs
|
2009
|
0.75
|
|
14
|
Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
|
Am J Clin Oncol
|
2017
|
0.75
|